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ABSTRACT
The bile salt export pump (BSEP) plays an important role in bile
acid excretion. Impaired BSEP function may result in liver injury.
Bile acids also undergo basolateral efflux, but the relative con-
tributions of biliary (CLBile) versus basolateral efflux (CLBL) clearance
to hepatocellular bile acid excretion have not been determined. In
the present study, taurocholic acid (TCA; a model bile acid)
disposition was characterized in human and rat sandwich-cultured
hepatocytes (SCH) combined with pharmacokinetic modeling. In
human SCH, biliary excretion of TCA predominated (CLBile 5
0.146 0.04 ml/min per g liver;CLBL5 0.0426 0.019ml/min per g
liver), whereas CLBile and CLBL contributed approximately equally
to TCA hepatocellular excretion in rat SCH (CLBile 5 0.34 6 0.07
ml/min per g liver; CLBL 5 0.26 6 0.07 ml/min per g liver).
Troglitazone decreased TCA uptake, CLBile, andCLBL; membrane
vesicle assays revealed for the first time that the major metabolite,
troglitazone sulfate, was a noncompetitive inhibitor of multidrug
resistance–associated protein 4, a basolateral bile acid efflux
transporter. Simulations revealed that decreased CLBile led to
a greater increase in hepatic TCA exposure in human than in rat
SCH. A decrease in both excretory pathways (CLBile and CLBL)
exponentially increased hepatic TCA in both species, suggesting
that 1) drugs that inhibit both pathwaysmay have a greater risk for
hepatotoxicity, and 2) impaired function of an alternate excretory
pathway may predispose patients to hepatotoxicity when drugs
that inhibit one pathway are administered. Simulations confirmed
the protective role of uptake inhibition, suggesting that a drug’s
inhibitory effects on bile acid uptake also should be considered
when evaluating hepatotoxic potential. Overall, the current study
precisely characterized basolateral efflux of TCA, revealed species
differences in hepatocellular TCA efflux pathways, and provided
insights about altered hepatic bile acid exposure when multiple
transport pathways are impaired.
Introduction
Bile acids are important endogenous molecules that are
involved in the digestion and absorption of fats and regulation
of lipid and glucose homeostasis (Hofmann, 1999a; Nguyen
and Bouscarel, 2008). However, bile acids can exert toxic
effects at supraphysiologic concentrations through disruption
of mitochondrial ATP synthesis, necrosis, and apoptosis (Perez
and Briz, 2009; Maillette de Buy Wenniger and Beuers, 2010);
thus, defects in excretion may lead to hepatic accumulation of
bile acids and subsequent hepatotoxicity.
Hepatic transport proteins play important roles in vectorial
transport of bile acids. Sodium-taurocholate cotransporting poly-
peptide (NTCP) and organic anion transporting polypeptides are
responsible for sodium-dependent and -independent uptake of bile
acids from sinusoidal blood into hepatocytes, respectively. Bile
acids in hepatocytes are excreted into bile across the canalicular
membrane, predominantly via the bile salt export pump (BSEP).
Consistent with the important role of BSEP in bile acid excretion,
impaired BSEP function due to genetic polymorphisms has been
shown to induce liver injury (e.g., progressive familial intrahepatic
cholestasis type II) (Jansen et al., 1999). Also, increasing evidence
suggests that inhibition of BSEP by drugs is associated with
cholestatic/mixed-type drug-induced liver injury (DILI) (Morgan
et al., 2010, 2013; Dawson et al., 2012; Pedersen et al., 2013).
In addition to BSEP-mediated canalicular excretion, bile
acids also are transported from the hepatocyte into sinusoidal
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blood via basolateral efflux transporters, including multidrug
resistance–associated protein (MRP) 3, MRP4, and organic
solute transporter a (OSTa)–OSTb. Expression levels of MRP3
andMRP4 are upregulated under cholestatic conditions, suggest-
ing that they function as a compensatory route of bile acid
excretion and thereby serve as an important part of adaptive
response (Akita et al., 2001; Trauner et al., 2005; Zollner et al.,
2007). OSTa–OSTb mediates basolateral efflux of bile acids from
enterocytes into the portal circulation by facilitated diffusion
(Ballatori et al., 2009), but the role of OSTa–OSTb in hepatic bile
acid efflux remains to be further characterized. Recently, Morgan
et al. (2013) reported that prediction of DILI was improved by
considering the inhibitory effect of a drug on MRP2, MRP3, and
MRP4, compared with BSEP inhibition alone. In addition,
studies from our laboratory demonstrated that MRP4 in-
hibition was associated with cholestatic/mixed DILI among
BSEP noninhibitors, emphasizing the role of MRP4 in DILI
(Köck et al., 2014).
DILI is one of the primary reasons for withdrawal of approved
drugs from the market and a major concern during drug
development (Watkins and Seeff, 2006). One prominent example
is troglitazone (TGZ), the first of the thiazolidinedione class of
antidiabetic drugs that was withdrawn fromworldwide markets
due to severe DILI. Although mechanisms of TGZ-mediated
hepatotoxicity remain unclear, in vitro vesicular transport as-
says demonstrated that TGZ and its major metabolite, TGZ
sulfate (TS), are potent BSEP inhibitors, suggesting a cholestatic
component in TGZ-induced hepatotoxicity (Funk et al.,
2001). TGZ also inhibits NTCP, MRP3, and MRP4 (Marion
et al., 2007; Morgan et al., 2013); although TS accumulates
extensively in hepatocytes (Funk et al., 2001; Lee et al.,
2010), the effect of TS on basolateral efflux transporters has
not been investigated.
Due to extensive biliary excretion, it generally has been
accepted that the contribution of basolateral efflux to hepato-
cellular bile acid excretion is minimal under normal conditions.
However, as proposed in the “hepatocyte hopping” theory of
bilirubin glucuronides (Iusuf et al., 2012), it is plausible that
bile acids may undergo extensive basolateral efflux (through
MRP3 and/or MRP4) and reuptake into downstream hepato-
cytes (through NTCP and/or organic anion-transporting poly-
peptide). This would prevent saturation of biliary transporters in
upstream hepatocytes and transfer bile acids to downstream
hepatocytes, protecting hepatocytes from bile acid toxicity. To our
knowledge, the contribution of basolateral efflux versus biliary
excretion to hepatocellular bile acid disposition has not been
precisely characterized.
The purpose of the present studies was to characterize
taurocholic acid (TCA) hepatobiliary disposition (basolateral
uptake, basolateral efflux, biliary excretion, flux from canalicu-
lar networks) in human and rat sandwich-cultured hepatocytes
(SCH) using a novel uptake and efflux protocol developed by our
laboratory combined with pharmacokinetic modeling (Pfeifer
et al., 2013). Results from the current investigation revealed that
species differences exist in cellular TCA efflux pathways in
human versus rat SCH; simulations suggested differential
hepatobiliary TCA disposition in human and rat SCH due to
inhibitors of canalicular excretion and/or basolateral efflux. This
novel finding might explain, in part, the underlying mecha-
nisms of species differences in hepatotoxicitymediated by BSEP
inhibitors. This study also investigated the effects of TGZ and its
metabolites on TCA disposition in human and rat SCH, and is
the first to report that TS inhibits MRP4, a basolateral bile acid
efflux transporter. Last, simulations based on the constructed
mechanistic models provided insights regarding altered hepatic
bile acid exposure when multiple bile acid transport pathways
are impaired.
Materials and Methods
All chemicals were purchased from Sigma-Aldrich (St. Louis,
MO) unless otherwise stated. TGZ [5-(4-[(6-hydroxy-2,5,7,8-
tetramethylchroman-2-yl)methoxy]benzyl)thiazolidine-2,4-dione] was
purchased from Cayman Chemical Company (Ann Arbor, MI). TS
(5-[[4-[[3,4-dihydro-2,5,7,8-tetramethyl-6-(sulfooxy)-2H-1-benzopyran-
2-yl]methoxy]phenyl]methyl]-2,4-thiazolidinedione) was kindly provided
byDaiichi-SankyoCo., Ltd. (Tokyo, Japan). TSwas also synthesized from
TGZ in-house as described by Saha et al. (2010). [3H]TCA (5 Ci/mmol)
and [3H]dehydroepiandrosterone sulfate (DHEAS; 79.5 Ci/mmol) were
purchased from PerkinElmer (Waltham, MA). Dimethylsulfoxide was
obtained fromFisher Scientific (Fairlawn,NJ). GIBCObrand fetal bovine
serum, recombinant human insulin, and Dulbecco’s modified Eagle’s
medium (DMEM)were purchased fromLife Technologies (Carlsbad, CA).
Insulin/transferrin/selenium culture supplement, BioCoat culture plates,
and Matrigel extracellular matrix were purchased from BD Biosciences
Discovery Labware (Bedford, MA).
Sandwich-Cultured Hepatocytes. Rat hepatocytes were iso-
lated from male Wistar rats (234–245 g; Charles River Laboratories,
Inc., Wilmington, MA) using a two-step collagenase perfusion method
as previously described (LeCluyse et al., 1996). Animals had free
access to water and food before surgery and were allowed to acclimate
for at least 5 days. All animal procedures complied with the guidelines
of the Institutional Animal Care and Use Committee (University of
North Carolina, Chapel Hill, NC). Rat hepatocytes were seeded onto
six-well BioCoat culture plates at a density of 1.75  106 cells/well
in seeding medium (DMEM containing 5% fetal bovine serum, 10 mM
insulin, 1 mM dexamethasone, 2 mM L-glutamine, 1% minimum
essential medium nonessential amino acids, 100 units/ml of penicillin
G sodium, and 100 mg/ml of streptomycin) as described previously
(Swift et al., 2010). Hepatocytes were incubated for 2 hours at 37C in
a humidified incubator (95% O2, 5% CO2) and allowed to attach to the
collagen substratum, after which time the medium was aspirated to
remove unattached cells and replaced with fresh medium. The next
day, cells were overlaid with BD Matrigel at a concentration of
0.25 mg/ml in ice-cold feeding medium (DMEM supplemented with
0.1 mM dexamethasone, 2 mM L-glutamine, 1% minimum essential
medium nonessential amino acids, 100 units/ml of penicillin G sodium,
100 mg/ml of streptomycin, and 1% insulin/transferrin/selenium).
The culture medium was changed daily until experiments were
performed on day 4. Fresh human SCH, seeded onto 24-well BioCoat
culture plates and overlaid with Matrigel, were purchased from
Triangle Research Laboratories (Research Triangle Park, NC). Fresh
human hepatocytes were obtained from two Caucasian females
[31 years old, body mass index (BMI) 29.1 kg/m2; 56 years old, BMI
22.3 kg/m2) and one African American female (48 years old, BMI
24.9 kg/m2). The culture medium (the same feeding medium used for
rat SCH) was changed daily until experiments were performed on
day 7.
Uptake and Efflux Studies in SCH. Uptake and efflux studies
of TCA were performed in human and rat SCH as previously described
(Pfeifer et al., 2013). In brief, on day 4 (rat) or day 7 (human) of culture,
SCHwere preincubated for 10minutes in 1.5ml/well (rat) or 0.3ml/well
(human) standard (Ca21-containing) or Ca21-free (Ca21/Mg21-free buffer
containing EGTA) Hanks’ balanced salt solution (HBSS). Incubating
SCH in Ca21-free HBSS disrupts the tight junctions that form the bile
canalicular networks (B-CLEAR technology; Qualyst Transporter Solu-
tions, Research Triangle Park, NC). For uptake and efflux studies with
TCA, SCH were treated with 1 mM [3H]TCA (400 nCi/ml) in 1.5 ml/well
(rat) or 0.3 ml/well (human) standard HBSS for 20 minutes at 37C.
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After the 20-minute uptake phase, buffers containing TCA were
removed, cells were washed twice with 1.5 ml/well (rat) or 0.3 ml/well
(human) standard or Ca21-free HBSS buffer at 37C, and the third
application of buffer was added to SCH for the 15-minute (rat) or
10-minute (human) efflux phase (Fig. 1). For determination of TGZ
effects on TCA disposition, SCHwere preincubated with 10mMTGZ for
30 minutes in 1.5 ml/well (rat) or 0.3 ml/well (human) standard HBSS
before 10-minute application of standard or Ca21-free HBSS. The rest
of the experiment (uptake and efflux) was performed as described
earlier. Preincubation was selected to minimize the inhibitory
effects of TGZ and its metabolites on TCA uptake, and to allow
enough time for the formation of TS, a potent BSEP inhibitor. TCA
accumulation in cells 1 bile (standard HBSS) and cells (Ca21-free
HBSS) during uptake (2, 5, 10, and 20 minutes in human SCH; 2, 5,
10, 15, and 20 minutes in rat SCH) and efflux (2, 3.5, 5, and 10
minutes in human SCH; 2, 3.5, 5, 10, and 15 minutes in rat SCH)
phases was determined by terminal sampling of n 5 3 wells at each
time point. During the efflux phase, incubation buffer (standard
HBSS or Ca21-free HBSS) also was collected at the end of each
incubation period. Cells were washed twice in ice-cold HBSS, and
were solubilized in 0.3 ml (24-well; human SCH) or 1ml (six-well; rat
SCH) 0.5% Triton X-100. Radioactivity in cell lysates and buffer
samples was quantified by liquid scintillation counting (Packard
TriCarb; PerkinElmer).
Pharmacokinetic Modeling. Pharmacokinetic modeling was
used to evaluate the hepatobiliary disposition of TCA (control), and
to determine the effects of TGZ on TCA disposition (1TGZ) in human
and rat SCH. A model scheme incorporating linear parameters
governing TCA disposition (Fig. 1) was fit to mass versus time data
from individual SCH experiments (Fig. 2). The model fitting was
performed with Phoenix WinNonlin, version 6.1 (Certara, St. Louis,
MO) using the stiff estimation method and a power model to account
for residual error. The following differential equations, which were
developed based on the model scheme depicted in Fig. 1, were fit
simultaneously to data generated in SCH in the presence of intact
and disrupted bile canaliculi for each condition (human and rat;
control and 1TGZ):
Mass in standard HBSS buffer:
dX 1Buffer
dt
5CLBL  C1Cell 1KFlux  XBile 2CLUptake
 C1Buffer 2KWash  X 1Buffer; X 1 Buffer 5Xdose
Mass in Ca21-free HBSS buffer:
dX 2Buffer
dt
5 ðCLBL 1CLBileÞ  C2Cell 2CLUptake  C2Buffer 2KWash
 X 2Buffer; X 2 Buffer 5Xdose
Fig. 1. Schemes depicting the uptake and efflux
protocol and the mechanistic model of [3H]TCA
disposition in SCH. (A) Uptake and efflux studies
were conducted in the presence of standard (+Ca2+)
Hanks’ balanced salt solution (Std HBSS). Tight
junctions remained sealed throughout the study
period. (B) Tight junctions remained open through-
out the study period by preincubating with Ca2+-free
HBSS, then performing an uptake phase in standard
HBSS to provide relief from the removal of Ca2+,
followed by a brief wash and efflux in Ca2+-free
HBSS. In the uptake and efflux protocols, the dashed
box represents preincubation with 10 mM TGZ in
standard HBSS for TGZ-treated groups. Gray shad-
ing represents inclusion of the substrate, 1 mM
[3H]TCA, in standard HBSS during the uptake
phase. Black shading represents 1-minute wash
followed by 10- (human SCH) or 15-minute (rat
SCH) efflux phase in standard or Ca2+-free HBSS. In
the model schemes, X, V, and C denote the mass of
TCA, compartmental volume, and TCA concentra-
tion, respectively. Subscripts on mass, volume, and
concentration terms denote the corresponding com-
partment in the model scheme. Superscripts repre-
sent the presence (+, intact tight junctions; cells +
bile) and absence (2, modulated tight junctions;
cells) of Ca2+ in the preincubation and efflux buffer.
CLuptake, CLBL, and CLBile represent clearance
values for uptake from buffer into hepatocytes, efflux
from hepatocytes into buffer, and canalicular excre-
tion from hepatocytes, respectively. KFlux represents
the first-order rate constant for flux from bile
networks into buffer.




5CLUptake  C1 or2Buffer 2 ðCLBL 1CLBileÞ
 C1 or2Cell ; X 1 or2 Cell 5 0
Mass in bile (standard HBSS):
dXBile
dt
5CLBile  C1Cell 2KFlux  XBile; X Bile 5 0










where CLBile is the biliary clearance, CLBL is the basolateral efflux
clearance, CLUptake is the uptake clearance, and variables and
parameters are defined as in Fig. 1, and Kwash was activated for
1 minute at the end of the 20-minute uptake phase and fixed at 1 
104 min21 based on simulations to eliminate the TCA dose from the
buffer compartment and represent the wash step. CCell represents the
intracellular concentration, calculated as XCell/VCell, where cellular
volume (VCell) was estimated based on the protein content of each
preparation, using a value of 7.4 ml/mg protein (Lee and Brouwer,
2010). CBuffer represents the buffer concentration, calculated as
XBuffer/VBuffer, where the buffer volume (VBuffer) was constant (1.5 ml
for rat SCH and 0.3 ml for human SCH). Initial parameter estimates
were obtained from noncompartmental analysis of SCH data, where
CLUptake was estimated from the initial (2 minutes) uptake data as
follows: CLUptake 5 (dXcells1bile/dt)/CBuffer. CLBL and CLBile were
estimated from efflux phase data under Ca21-free conditions, where
(CLBL 1 CLBile) 5 X
2
Buffer,0-15min/AUCcells,0-15min (area under the
cellular TCA concentration versus time curve from 0 to 15 minutes,
obtained using the linear trapezoidal rule). KFlux, which represents
the flux of substrate out of bile networks in standard HBSS
conditions, was estimated initially from simulations using Berkeley-
Madonna. The impact of impaired function of canalicular and/or
basolateral efflux transporters on hepatic TCA exposure in human
and rat SCH was simulated using the TCA model and parameter
estimates (Fig. 1; Table 1); parameters representing transport-mediated
efflux (CLBL and CLBile) were decreased by 10-fold in isolation, or in
combination, in human and rat SCH; the resulting changes in
predicted cellular TCA concentrations are plotted in Fig. 4. To
determine the net effect of impaired function of uptake and/or efflux
(basolateral and canalicular) transporters on hepatic TCA expo-
sure in human SCH, simulations were performed by decreasingCLUptake
and CLEfflux (sum of biliary and basolateral efflux clearances; CLBL 1
CLBile) gradually by 10- to 100-fold in combination; it was assumed
that both efflux pathways (CLBL and CLBile) were impaired to the same
extent. Simulated cellular TCA concentrations are presented in Fig. 5.
All simulations were performed using Berkeley-Madonna version
8.3.11.
Membrane Vesicles. Human MRP4 plasmid [pcDNA3.1(2)-MRP4]
was provided by Dr. Dietrich Keppler (German Cancer Research
Center, Heidelberg, Germany). Human embryonic kidney 293T cell
lines stably transfected with pcDNA3.1(2)-MRP4 or an empty plas-
mid vector (control) were established as previously described (Köck
et al., 2014). Membrane vesicles were prepared from these cell lines,
and transport experiments were carried out by a rapid filtration assay
as described previously (Ghibellini et al., 2008). In brief, membrane
vesicles (5 mg of protein) were incubated at 37C in Tris-sucrose buffer
(TSB; 50 mM Tris-HCl/250 mM sucrose) containing 10 mM MgCl2,
10 mM creatine phosphate, 100 mg/ml creatine kinase, 4 mM ATP or
AMP, and [3H]DHEAS (0.7 mCi/ml) in the absence and presence of TS,
in a volume of 50 ml. After incubation for 2 minutes, the reaction was
stopped by the addition of 0.8 ml of ice-cold TSB and immediately
applied to a glass fiber filter (type A/E; Pall Corp., Port Washington,
NY) and washed twice with 2ml of ice-cold TSB. Filters weremixed by
vortexing in 5 ml of scintillation fluid, and radioactivity was quan-
tified by liquid scintillation counting (Packard TriCarb). The ATP-
dependent uptake of substrate was calculated by subtracting substrate
uptake in the presence of AMP from substrate uptake in the presence
of ATP. The MRP4-dependent uptake of substrate was calculated
by subtracting ATP-dependent uptake in MRP4-overexpressing
vesicles from that in control vesicles. Initially, the inhibitory effect
of TS (10 mM) on MRP4-dependent transport of [3H]DHEAS (2 mM)
was evaluated in the presence or absence of 3 mM glutathione (GSH).
Further studies were performed using concentration ranges of
[3H]DHEAS (0.5–20 mM) and TS (5–50 mM) in the absence of GSH to
determine the inhibition constant (Ki). Initial estimates of Ki values
and the type of inhibition were derived from Dixon plots of TS
concentrations versus 1/velocity data. Then the kinetic parameters
(Km, Vmax, and Ki) and type of inhibition were determined by fitting
competitive, noncompetitive, and uncompetitive models to the un-
transformed data by nonlinear regression analysis using Phoenix

























where S represents the concentration of [3H]DHEAS, I represents the
concentration of TS, and V denotes the rate of [3H]DHEAS transport.
The best-fit model was assessed from visual inspection of the observed
versus predicted data and Akaike Information Criterion (AIC).
Representative data from n 5 2 independent experiments in triplicate
are presented in Fig. 3.
Data Analysis. TCA accumulation was corrected for nonspecific
binding to the BioCoat plate without cells, and normalized to
protein concentration measured by the BCA protein assay (Pierce
Chemical, Rockford, IL). The intracellular concentration of TCA
was obtained by dividing TCA accumulation (picomoles per milli-
gram protein) by the previously reported hepatocyte volume (7.4 ml/mg
protein) (Lee and Brouwer, 2010). Apparent (CLBile,app) and intrinsic
(CLBile,int) biliary clearance values were calculated using B-CLEAR








where AUCBuffer;02 t is the area under the TCA buffer concentration
versus time curve, which is the product of the initial TCA buffer
concentration (1 mM) and the incubation time (t), assuming that
sink conditions of TCA in the buffer are maintained (concentration
changes ,10% during the uptake phase). AUCCell;02 t is the area
under the TCA cellular concentration versus time curve, which was
obtained using the linear trapezoidal rule. Clearance units (micro-
liters per minute per milligram protein) were converted to milliliters
per minute per gram liver based on the protein content in liver tissue
(90 and 112 mg protein/g liver for human and rat, respectively)
(Sohlenius-Sternbeck, 2006). The paired Student’s t test was used to
compare parameters in the presence or absence of TGZ preincubation.
In all cases, P , 0.05 was considered statistically significant. All
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statistical analyses were performed using SigmaStat 3.5 (Systat
Software, San Jose, CA).
Results
TCA Disposition in Human and Rat SCH with and
without TGZ Preincubation. TCA uptake and efflux stud-
ies were conducted as described in Fig. 1. The mass-time
profiles of TCA in cells 1 bile and cells (during the uptake and
efflux phases) and buffer (during the efflux phase) in human
and rat SCH in the absence (control) and presence (1TGZ) of
TGZ preincubation are presented in Fig. 2. Under all conditions,
TCA accumulation in cells 1 bile and cells increased during the
uptake phase and decreased during the efflux phase. Appear-
ance of TCA in the standard and Ca21-free HBSS buffer
increased during the efflux phase. TGZ preincubation decreased
TCA accumulation in cells 1 bile, cells, and the efflux into
buffers in both human and rat SCH.CLBile,app of TCA during the
uptake phase was also significantly decreased after preincuba-
tion with TGZ compared with the control group, indicating
that TGZ decreased uptake and/or biliary excretion of TCA; in
human SCH, CLBile,app values after 10-minute uptake (standard
B-CLEAR method) in control and 1TGZ groups were 1.1 6 0.3
and 0.106 0.02 ml/min per g liver, respectively (P5 0.035). The
corresponding values in rat SCH were 0.48 6 0.08 and 0.07 6
0.01 ml/min per g liver, respectively (P 5 0.008). TCA CLBile,int
also was significantly decreased after TGZ preincubation,
suggesting that TGZ decreased TCA biliary excretion; in
human SCH, CLBile,int values after 10-minute uptake in
control and 1TGZ groups were 0.31 6 0.07 and 0.15 6
0.09 ml/min per g liver, respectively (P 5 0.004). The
corresponding values in rat SCH were 0.62 6 0.11 and
0.22 6 0.08 ml/min per g liver, respectively (P 5 0.049).
Parameter estimates recovered from fitting differential
equations (see Materials and Methods) based on the model
scheme in Fig. 1 to TCA accumulation data from independent
SCH preparations are presented in Table 1. In the absence
of TGZ preincubation (control), human SCH showed greater
CLUptake, slightly lower CLBile, and notably lower CLBL
relative to rat SCH. This is consistent with greater cellular
accumulation of TCA observed in human SCH (Fig. 2).
Interestingly, CLBile was about 3.3-fold greater than CLBL
in human SCH, whereas CLBile and CLBL showed a similar
contribution to the total cellular efflux of TCA in rat SCH
in the absence of TGZ. In human SCH, TGZ preincubation
significantly decreased CLUptake (P 5 0.017); there were
trends toward decreased CLBL and CLBile after TGZ pre-
incubation compared with the control groups. In rat SCH,
CLBile was significantly decreased after TGZ preincubation
(P 5 0.017); there were trends toward decreased CLUptake
and CLBL after TGZ preincubation compared with the
control groups. However, these differences failed to reach
statistical significance due to large variability in mean
differences.
Inhibitory Effects of TS on MRP4-Mediated [3H]DHEAS
Transport in Membrane Vesicles. The inhibitory effects of
TS on MRP4, a basolateral bile acid efflux transporter, were
evaluated using membrane vesicles prepared from human
embryonic kidney 293T cells overexpressing MPR4 or control
cells. TS (10 mM) inhibited MRP4-mediated transport of
[3H]DHEAS (2 mM) by 78 and 72% in the absence and presence
of GSH, respectively (Fig. 3A). Inhibition of MRP4-mediated
[3H]DHEAS transport by TS was determined in two indepen-
dent membrane vesicle studies over a range of substrate
concentrations (DHEAS, 0.5–20 mM) and inhibitor concentra-
tions (TS, 5–50 mM). In both studies, the noncompetitive
inhibitionmodel best described the inhibition data visually and
generated the lowest AIC value; AIC values for competitive,
noncompetitive, and uncompetitive inhibition models were
Fig. 2. [3H]TCA mass versus time data in rat and human SCH in the absence (control) or presence of 10 mM TGZ preincubation. Closed symbols/solid
lines represent [3H]TCA in cells + bile (top) or standard HBSS (bottom), and open symbols/dashed lines represent [3H]TCA in cells (top) or Ca2+-free
HBSS (bottom). The simulated mass-time profiles were generated from the relevant equations based on the model scheme depicted in Fig. 1, and the
final parameter estimates are reported in Table 1. Data (picomoles per milligram protein) represent the mean 6 S.E.M. (n = 3 SCH preparations in
triplicate per group).
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632.4, 628.9, and 664.6, respectively, in the first study, and
were 740.0, 738.3, and 786.0, respectively, in the second study.
Ki values based on a noncompetitive inhibition model were
8.06 0.70 and 8.56 1.2 mM in the first and the second studies,
respectively. A representative fit of the noncompetitive in-
hibition model to the data is presented in Fig. 3B.
Impact of Impaired Function of Canalicular versus
Basolateral Efflux Transporters on Hepatic TCA Ex-
posure. The altered hepatobiliary disposition of TCA due
to impaired function of bile acid efflux transporters was
simulated based on the TCA model described in this report
(Fig. 1; Table 1). Simulated hepatic TCA concentrations, up to
and including steady state (CH,ss) in human and rat SCH, are
shown in Fig. 4, A and B, respectively. CLUptake of TCA in rat
SCH might have been underestimated compared with rats in
vivo because it has been reported that TCA uptake clearance
was decreased by 5-fold in rat SCH on day 4 compared with
day 0 due to decreased Ntcp protein expression, whereas TCA
uptake clearance remained unchanged over time in human
SCH (Liu et al., 1998; Kotani et al., 2011; Tchaparian et al.,
2011). To account for decreased Ntcp function over days of
culture, simulations were also performed with a 5-fold higher
CLUptake in rat SCH (Fig. 4C). TCACH,ss was higher in human
SCH (11.1 mM) compared with rat SCH (1.9 mM) (Fig. 4, A and
B); this is consistent with the observed higher cellular TCA
accumulation during uptake and efflux studies compared with
rat SCH (Fig. 2). However, TCA CH,ss in rat SCH with 5-fold
greater CLUptake (9.1 mM) is comparable to that in human
SCH (Fig. 4, A and C). Simulations revealed that in human
SCH, a 10-fold decrease in CLBile increased TCA CH,ss by
2.9-fold compared with control, whereas a 1.3-fold increase
in TCA CH,ss occurred relative to control when CLBL was
decreased by 10-fold (Fig. 4A). Interestingly, a 10-fold decrease
in both CLBile and CLBL increased TCA CH,ss by 7.0-fold
compared with control, which is a greater than proportional
increase compared with inhibiting either pathway in isolation.
Simulations in rat SCH revealed that TCA CH,ss was increased
by 2.0- and 1.6-fold when CLBile and CLBL were decreased by
10-fold, respectively, relative to control (Fig. 4B). TCA CH,ss
increased by 9.3-fold relative to control when both CLBile and
CLBL were decreased by 10-fold; similar to human SCH
simulations, the increase in CH,ss is greater than proportional
compared with conditions in which either pathway is impaired
in isolation. The same trends were observed in rat SCH when
5-fold greaterCLUptake was simulated (Fig. 4C); the fold increase
in TCACH,ss was 1.9, 1.6, and 7.3 relative to control whenCLBile,
CLBL, and both CLBile and CLBL were decreased 10-fold,
respectively.
Impact of Impaired Function of Uptake versus Efflux
Transporters on Hepatic TCA Exposure in Human
SCH. Hepatic bile acid concentrations are determined by
both hepatic uptake and efflux processes; drugs that inhibit
efflux transporters often also inhibit uptake transporters. To
understand the net effects of impaired function of uptake and
efflux transporters on hepatic TCA exposure, TCA CH,ss in
human SCH was simulated based on various values of
Fig. 3. Inhibition of MRP4-mediated transport of [3H]DHEAS by TS in membrane vesicles from MRP4-overexpressing and control human embryonic
kidney 293T cells. (A) Effect of GSH (3 mM) on MRP4-mediated transport of 2 mM [3H]DHEAS and inhibition by 10 mM TS. (B) Effect of increasing
concentrations of TS (0, 5, 10, and 50 mM) on MRP4-mediated [3H]DHEAS (2 minutes, 0.5–20 mM) transport in the absence of GSH. Each point
represents the mean 6 S.D. A noncompetitive inhibition model best described the data. Lines represent model fits based on the noncompetitive
inhibition model. Representative plots from n = 2 independent studies are presented. The estimated Ki values based on a noncompetitive inhibition
model were 8.0 6 0.7 and 8.5 6 1.2 mM from each study.
TABLE 1
Summary of recovered parameter estimates based on the model scheme depicted in Fig. 1 describing TCA
disposition in human and rat SCH without (control) or with 10 mM troglitazone (+TGZ) preincubation
Human and rat SCH were treated with 1 mM [3H]TCA (see Fig. 1 for details of incubation conditions), and the model was
fit simultaneously to all data from each preparation. Data are presented as the mean 6 S.D. of individual fits from n = 3
SCH preparations.
Conditions CLUptake CLBile CLBL KFlux
ml/min per g liver min21
Human SCH
Control 2.2 6 0.4 0.14 6 0.04 0.042 6 0.019 0.043 6 0.015
+TGZ 0.23 6 0.04* 0.084 6 0.069 0.022 6 0.018 0.070 6 0.036
Rat SCH
Control 1.2 6 0.5 0.34 6 0.07 0.26 6 0.07 0.053 6 0.015
+TGZ 0.20 6 0.04 0.18 6 0.05* 0.22 6 0.06 0.077 6 0.038
*Significantly different from control (P , 0.05).
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CLUptake and CLEfflux (defined as CLBile 1 CLBL) (Fig. 5).
When CLUptake remained unchanged (for example, fractional
inhibition of CLUptake 5 0), TCA CH,ss increased exponentially
as the fractional inhibition of CLEfflux increased. On the
other hand, CH,ss decreased proportionally as the fractional
inhibition of CLUptake increased, when CLEfflux remained
unchanged (for example, fractional inhibition of CLEfflux 5 0).
When the fractional inhibition of CLUptake and CLEfflux was
the same, TCA CH,ss remained unchanged (fold change 5 1).
If the fractional inhibition of CLUptake was greater than the
fractional inhibition of CLEfflux, then TCA CH,ss was decreased
(fold change , 1). If the fractional inhibition of CLUptake was
less than the fractional inhibition of CLEfflux, then the fold
change in TCA CH,ss was greater than 1; TCA CH,ss increased
exponentially with increasing fractional inhibition of CLEfflux,
but the fold change in TCA CH,ss decreased with increasing
fractional inhibition of CLUptake. Notably, a greater than
10-fold increase in TCA CH,ss was observed only when the
fractional inhibition of CLUptake was less than 0.6.
Discussion
The present study determined the hepatobiliary disposition
of TCA in human and rat SCH using a novel uptake and efflux
protocol recently developed in our laboratory combined with
pharmacokinetic modeling (Pfeifer et al., 2013). The results
demonstrated that species differences exist in the hepato-
cellular excretion of TCA; in human SCH, biliary excretion
predominated, whereas biliary excretion and basolateral ef-
flux contributed approximately equally to hepatocellular TCA
excretion in rat SCH (Table 1). Jemnitz et al. (2010) reported
that basolateral and biliary excretion contribute equally to
TCA efflux in human SCH, whereas basolateral efflux was the
dominant cellular efflux pathway of TCA in rat SCH. The
likely reason for these discrepancies is that these investi-
gators did not account for the TCA “flux” from the canalicular
spaces into the buffer, which results from regular “pulsing” of
the bile canaliculi in SCH (KFlux in Fig. 1) (Pfeifer et al., 2014).
Regular, ordered contraction of bile canaliculi has been
reported previously in isolated couplets and cultured hepa-
tocytes (Oshio and Phillips, 1981; Phillips et al., 1982), and
has been shown to facilitate bile flow in vivo in rat liver
(Watanabe et al., 1991). In the study by Jemnitz et al. (2010),
basolateral effluxwas evaluated bymeasuring TCA in standard
buffer during the efflux phase. However, the amount of TCA
that appeared in the buffer during the efflux phase was
actually the sum of basolateral efflux and flux from the bile
canalicular spaces, which led to an overestimation of basolateral
efflux. To circumvent these issues and accurately estimate the
relative contributions of CLBL, CLBile, and KFlux, pharmacoki-
netic modeling was used in the current study.
Troglitazone, a known hepatotoxic compound, was selected
in the current study because disposition of TGZ and its
derived metabolites was well characterized in human and rat
SCH (Lee et al., 2010). After preincubation with TGZ, CLBile
was significantly decreased (rat) or tended to decrease
(human) compared with control (Table 1), consistent with
reported inhibitory effects of TGZ and TS on BSEP (Funk
et al., 2001; Dawson et al., 2012). Interestingly, CLBL tended
to decrease after TGZ preincubation compared with control,
Fig. 5. Net effects of inhibition of uptake and efflux transporters on
hepatic TCA exposure. Cellular TCA concentrations in human SCH were
simulated as a function of decreased (10- to 100-fold) CLUptake and CLEfflux
(defined as CLBL + CLBile); both efflux pathways (CLBL and CLBile) were
assumed to be impaired to the same extent. The z-axis represents the fold
change in steady-state hepatic TCA concentrations: 10- to 100-fold (red),
5- to 10-fold (orange), 1- to 5-fold (light green), 0.1- to 1-fold (dark green),
and 0.001- to 0.1-fold (blue).
Fig. 4. Simulations depicting the impact of impaired function of canalicular and/or basolateral efflux transporters on hepatic TCA exposure. Cellular
TCA concentrations in human and rat SCH were simulated based on the TCA model scheme depicted in Fig. 1 and parameter estimates (Table 1) for
human SCH (A), rat SCH (B), and rat SCH where CLUptake was 5 the value listed in Table 1 (C). Parameters representing transport-mediated efflux
(CLBL and CLBile) were decreased by 10-fold in isolation, or in combination, to represent impaired function of canalicular efflux transporters (solid line
with open circle), basolateral efflux transporters (dashed line), and both pathways (dashed line with closed circle). Simulations were performed for 200
minutes to obtain steady-state intracellular concentrations; the time to reach steady state was longer when efflux pathways were impaired compared
with control (solid line).
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suggesting that TGZ and/or TS also might inhibit basolateral
efflux of TCA. TGZ has been reported to inhibit the baso-
lateral efflux transporters MRP3 and MRP4 (Morgan et al.,
2013), but hepatic TGZ concentrations are minimal, whereas
TS accumulates in hepatocytes due to extensive hepatic
metabolism of TGZ (Funk et al., 2001; Lee et al., 2010). Thus,
inhibitory effects of TS on MRP4-mediated transport were
investigated. MRP4 was selected because TCA is transported
by human MRP4, but not by human MRP3 (Akita et al., 2002;
Rius et al., 2006). Since GSH is cotransported with bile acids
by MRP4 (Rius et al., 2006), the inhibitory effect of TS at
10 mM was tested initially in the absence and presence of
GSH. TS inhibited MRP4-mediated transport of [3H]DHEAS
to a similar extent regardless of GSH, suggesting that the
inhibitory effects of TS on MRP4 are independent of GSH
(Fig. 3A). Further studieswere performed in the absence of GSH,
and revealed that TS inhibited MRP4-mediated [3H]DHEAS
transport by noncompetitive inhibition, with a Ki value of 8 mM
(Fig. 3B).
In addition to inhibition of efflux, CLUptake of TCA was
significantly decreased (human) or showed trends toward
a decrease (rat) compared with control after TGZ preincuba-
tion (Table 1). Although TGZ is a potent inhibitor of NTCP/
Ntcp-mediated bile acid uptake (Marion et al., 2007), TGZ
concentrations in the buffer were minimal during the uptake
phase because TGZ-containing buffer was removed and replaced
with TGZ-free buffer during the 10-minute preincubation (stan-
dard or Ca21-free buffers) as well as the 20-minute uptake phase.
These data suggest that TGZ might inhibit NTCP/Ntcp by
mechanisms other than direct inhibition; further studies are
needed to characterize the precise mechanism(s) of inhibition.
Preclinical animals often are less sensitive to bile acid–mediated
DILI compared with humans, and thus, do not reliably
predict human hepatotoxicity. Potential reasons include
species differences in toxic bile acid composition, substrate
and/or inhibitor specificity of bile acid transporters, and
metabolism/detoxification pathways of drugs as well as bile
acids (Setchell et al., 1997; Hofmann, 2004; Leslie et al.,
2007; Chiang, 2009). In addition, differential inhibition of
hepatocellular excretion pathways, as demonstrated in the
current study, may contribute to species differences in bile
acid–mediated hepatotoxicity. Simulations revealed that
impaired function of canalicular and/or basolateral efflux
transporters led to differential hepatobiliary disposition
of TCA in human and rat SCH. In human SCH, hepatic
TCA concentrations, which are relevant to hepatotoxicity,
were increased 2.9-fold relative to control when canalicular
transporter function was impaired, whereas impaired func-
tion of basolateral efflux transporters minimally increased
hepatic TCA concentration (1.3-fold) (Fig. 4A). This was
expected due to the predominant role of biliary excretion and
the minor contribution of basolateral efflux to the overall
hepatocellular excretion of TCA in human SCH. Interestingly,
impaired function of both canalicular and basolateral efflux
transporters further increased hepatic TCA concentrations by
7-fold compared with control (Fig. 4A), suggesting that baso-
lateral efflux, despite serving as aminor route of hepatic excretion
under normal conditions, plays an important role as a com-
pensatory efflux pathwaywhen canalicular excretion is impaired
in human hepatocytes.
Expression and/or function of Ntcp has been reported to
decrease over days of culture in rat SCH, whereas NTCP
expression remains constant in human SCH; in rat SCH, TCA
uptake clearance was decreased 5-fold on day 4 compared
with day 0 (Liu et al., 1998; Kotani et al., 2011; Tchaparian
et al., 2011). Thus, the CLUptake of TCA is likely under-
estimated in rat SCH, but not in human SCH. To account for
the decreased function of Ntcp in day 4 rat SCH, simulations
were performed in rat SCH with an CLUptake estimate
obtained in day 4 rat SCH (1 CLUptake) as well as a 5-fold
greater CLUptake (5 CLUptake). Although robust functional or
quantitative proteomics data for BSEP, MRP3, and MRP4 in
SCH over time do not exist, available data suggest that Bsep
protein expression in rat SCH and MRP3/Mrp3 and MRP4/
Mrp4 in rat and human SCH remain relatively unchanged
over days of culture under our culture conditions (Swift et al.,
2010; Tchaparian et al., 2011).
In both human and rat SCH, an exponential increase in
hepatic TCA concentrations was only observed when the
function of both efflux pathways was decreased (Fig. 5). These
results are consistent with the mathematical relationship
that governs fold change in cellular exposure: 1/(12 fe), where
fe is the total fraction excreted by all pathways (biliary or baso-
lateral) (Zamek-Gliszczynski et al., 2009). Zamek-Gliszczynski et al.
demonstrated that, if multiple excretion pathways exist, minor
changes in exposure (,2-fold) are expected when a transport
pathway that contributes to no more than 50% of total excretion
is impaired, as noted when biliary excretion (rat) or basolateral
efflux (human and rat) pathways alone are decreased in the
current study. However, hepatic exposure increases exponen-
tially in response to loss of function of transport pathways that
contribute to .50% of total excretion, as noted in the current
study when both biliary excretion and basolateral efflux trans-
porters are impaired.
Bile acids undergo efficient enterohepatic recirculation;
only ∼5% of the bile acid pool is synthesized in hepatocytes,
whereas the remaining 95% is reabsorbed from the intestinal
lumen after biliary excretion and taken up into hepatocytes
(Hofmann, 1999b). Therefore, in addition to canalicular and
basolateral efflux transporters, hepatic bile acid exposure is
also regulated by hepatic uptake transporters. Inhibition of
bile acid efflux transporters by drugs is reported to be
associated with cholestatic/mixed-type DILI, but often, these
drugs also inhibit uptake transporters, which may exert pro-
tective effects (Leslie et al., 2007); the net effect will be
determined by the relative extent (potency) of uptake inhi-
bition versus efflux inhibition. As might be expected, simu-
lations suggest that hepatic TCA exposure increases only when
the extent of efflux inhibition exceeds that of uptake inhibition
(Fig. 5). Notably, fractional inhibition of CLUptake . 0.6 pre-
vents hepatic TCA exposure from increasing bymore than 10-fold,
thereby confirming the protective effects of uptake inhibi-
tion. Simulations in the current study were performed using
a constant fractional inhibition of uptake and efflux trans-
porters throughout the simulation, assuming steady-state
drug (inhibitor) concentrations in the medium and in the
cell. In reality, drug concentrations change over time. Thus,
dynamic changes in inhibitor concentrations should be consid-
ered by incorporating drug disposition into the model to more
accurately predict altered bile acid disposition by drugs.
In the current study, species differences in hepatic excretion
of TCA in human and rat SCH were identified. In human SCH,
biliary excretion predominated, whereas biliary excretion and
basolateral efflux contributed approximately equally to TCA
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efflux in rat SCH. As a result, the hepatic accumulation of TCA
in rat SCH due to inhibition of BSEP alone might not be as
extensive as that observed in human SCH. In human and rat
SCH, inhibition of both excretion pathways led to exponential
increases in hepatic TCA exposure, suggesting that inhibition
of both excretion pathways might increase DILI liability.
Alternatively, administration of a drug that inhibits one ex-
cretion pathway may predispose individuals with impaired
transport function (due to disease or genetic polymorphisms) in
the alternate pathway to hepatic bile acid accumulation and
subsequent DILI. Simulations confirmed that uptake inhibi-
tion plays a protective role by helping minimize hepatic bile
acid accumulation. This work emphasizes that the inhibitory
effects of a drug on bile acid transporters mediating uptake as
well as multiple efflux pathways should be considered when
evaluating the hepatotoxic potential of drugs.
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